Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Alnylam Pharmaceuticals
company
About
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
- 1001 - 5000
Details
- Last Funding Type
- Private Equity（PE）
- Last Funding Money Raised
- $24.60M
- Industries
- Biotechnology,Health Care,Medical,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2002
- Number Of Employee
- 1001 - 5000
- Operating Status
- Active
Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$834.60M
Alnylam Pharmaceuticals has raised a total of
$834.60M
in funding over 2 rounds. Their latest funding was raised on
Apr 8, 2019 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 8, 2019 | Post-IPO Equity | $800M | 1 |
Regeneron
|
— | Detail |
| Mar 28, 2011 | Post-IPO Equity | $10M | 1 |
Takeda
|
— | Detail |
| Jul 7, 2003 | Private Equity（PE） | $24.60M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
2
4
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Regeneron
|
Yes | Post-IPO Equity |
|
Takeda
|
Yes | Post-IPO Equity |
Merck
|
— | Private Equity（PE） |
ARCH Venture Partners
|
— | Private Equity（PE） |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
